Page last updated: 2024-08-23

substance p and Atherosclerotic Parkinsonism

substance p has been researched along with Atherosclerotic Parkinsonism in 11 studies

Research

Studies (11)

TimeframeStudies, this research(%)All Research%
pre-19904 (36.36)18.7374
1990's5 (45.45)18.2507
2000's1 (9.09)29.6817
2010's1 (9.09)24.3611
2020's0 (0.00)2.80

Authors

AuthorsStudies
Thornton, E; Vink, R1
Lavoie, B; Parent, A1
Drago, J; Finkelstein, DI; Kola, I; Lakso, M; Lawrence, AJ; McManus, JF; Natoli, AL; Padungchaichot, P; Sumarsono, SH; Westphal, H; Wong, JY; Wreford, N1
Gresch, PJ; Walker, PD1
Aoyama, S; Borrelli, E; Kase, H1
Godlevskiĭ, LS; Kryzhanovskiĭ, GN; Kucherianu, VG; Mazarati, AD1
Bennett, JP; Orosz, D1
Allen, JM; Close, SP; Cross, AJ; Crow, TJ; Ghatei, MA; Marriott, AS; McGregor, GP; Pay, S; Tyers, MB; Yeats, JC1
Cumming, P; Radke, JM; Vincent, SR1
Barker, R1
Atadzhanov, MA; Kryzhanovskiĭ, GN; Kucherianu, VG1

Reviews

1 review(s) available for substance p and Atherosclerotic Parkinsonism

ArticleYear
Adrenal grafting for Parkinson's disease: a role for substance P.
    The International journal of neuroscience, 1989, Volume: 46, Issue:1-2

    Topics: Adrenal Medulla; Animals; Nerve Growth Factors; Parkinson Disease, Secondary; Substance P

1989

Other Studies

10 other study(ies) available for substance p and Atherosclerotic Parkinsonism

ArticleYear
Treatment with a substance P receptor antagonist is neuroprotective in the intrastriatal 6-hydroxydopamine model of early Parkinson's disease.
    PloS one, 2012, Volume: 7, Issue:4

    Topics: Animals; Anti-Inflammatory Agents; Blood-Brain Barrier; Cells; Dopaminergic Neurons; Inflammation; Male; Motor Activity; Neurokinin-1 Receptor Antagonists; Neuroprotective Agents; Oxidopamine; Parkinson Disease, Secondary; Piperidines; Rats; Rats, Sprague-Dawley; Rotarod Performance Test; Substance P; Substantia Nigra; Tryptophan

2012
The heterogeneity of the mesostriatal dopaminergic system as revealed in normal and parkinsonian monkeys.
    Advances in neurology, 1993, Volume: 60

    Topics: Animals; Brain Mapping; Calbindins; Corpus Striatum; Dopamine; Enkephalin, Methionine; Female; Immunoenzyme Techniques; Macaca fascicularis; Mesencephalon; Nerve Degeneration; Neural Pathways; Neurons; Parkinson Disease, Secondary; Receptors, Dopamine; S100 Calcium Binding Protein G; Substance P; Tyrosine 3-Monooxygenase

1993
Targeted expression of a toxin gene to D1 dopamine receptor neurons by cre-mediated site-specific recombination.
    The Journal of neuroscience : the official journal of the Society for Neuroscience, 1998, Dec-01, Volume: 18, Issue:23

    Topics: Animals; Apoptosis; Basal Ganglia; Diphtheria Toxin; Enkephalins; Gene Expression Regulation, Enzymologic; Glial Fibrillary Acidic Protein; Gliosis; In Situ Hybridization; In Situ Nick-End Labeling; Integrases; Mice; Mice, Transgenic; Microscopy, Electron; Movement Disorders; Myoclonus; Neurons; Parkinson Disease, Secondary; Phenotype; Radioligand Assay; Receptors, Dopamine D1; RNA, Messenger; Substance P; Viral Proteins

1998
Serotonin-2 receptor stimulation normalizes striatal preprotachykinin messenger RNA in an animal model of Parkinson's disease.
    Neuroscience, 1999, Volume: 93, Issue:3

    Topics: Amphetamines; Animals; Corpus Striatum; Disease Models, Animal; Dopamine; Drug Administration Schedule; Gene Expression Regulation; In Situ Hybridization; Male; Neural Pathways; Oxidopamine; Parkinson Disease, Secondary; Protein Precursors; Raphe Nuclei; Rats; Rats, Sprague-Dawley; Receptor, Serotonin, 5-HT2A; Receptor, Serotonin, 5-HT2C; Receptors, Serotonin; RNA, Messenger; Serotonin; Serotonin Receptor Agonists; Substance P; Substantia Nigra; Tachykinins

1999
Rescue of locomotor impairment in dopamine D2 receptor-deficient mice by an adenosine A2A receptor antagonist.
    The Journal of neuroscience : the official journal of the Society for Neuroscience, 2000, Aug-01, Volume: 20, Issue:15

    Topics: Adenosine; Animals; Antihypertensive Agents; Antineoplastic Agents; Enkephalins; Gait; Gene Expression; Mice; Mice, Inbred C57BL; Mice, Knockout; Motor Activity; Parkinson Disease, Secondary; Phenethylamines; Purinergic P1 Receptor Antagonists; Purines; Radioligand Assay; Receptor, Adenosine A2A; Receptors, Dopamine D2; Receptors, Purinergic P1; RNA, Messenger; Substance P; Tritium

2000
[Effects of intranasally administered substance P in parkinsonian syndrome].
    Biulleten' eksperimental'noi biologii i meditsiny, 1992, Volume: 113, Issue:1

    Topics: Administration, Intranasal; Animals; Caudate Nucleus; Parkinson Disease, Secondary; Rats; Substance P

1992
Baseline and apomorphine-induced extracellular levels of nigral substance P are increased in an animal model of Parkinson's disease.
    European journal of pharmacology, 1990, Jul-17, Volume: 182, Issue:3

    Topics: Animals; Apomorphine; Dialysis; Disease Models, Animal; Dopamine; Ganglia, Sympathetic; Hydroxydopamines; Neurons; Oxidopamine; Parkinson Disease, Secondary; Rats; Rats, Inbred Strains; Substance P; Substantia Nigra

1990
Neuropeptides and dopamine in the marmoset. Effect of treatment with 1-methyl-4-phenyl-1, 2, 3, 6 tetrahydropyridine (MPTP): an animal model for Parkinson's disease?
    Brain : a journal of neurology, 1986, Volume: 109 ( Pt 1)

    Topics: 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; Animals; Brain Chemistry; Callitrichinae; Cholecystokinin; Disease Models, Animal; Dopamine; Female; Kidney; Male; Neurotensin; Parkinson Disease, Secondary; Pyridines; Substance P; Vasoactive Intestinal Peptide

1986
Effects of MPTP poisoning on central somatostatin and substance P levels in the mouse.
    European journal of pharmacology, 1987, Jan-28, Volume: 134, Issue:1

    Topics: 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; Animals; Catecholamines; Corpus Striatum; Male; Mice; Mice, Inbred C57BL; Parkinson Disease, Secondary; Pyridines; Radioimmunoassay; Somatostatin; Substance P

1987
[Effects of substance P on experimental parkinsonian syndrome].
    Biulleten' eksperimental'noi biologii i meditsiny, 1989, Volume: 108, Issue:10

    Topics: 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; Animals; Caudate Nucleus; Extrapyramidal Tracts; Male; Motor Cortex; Parkinson Disease, Secondary; Rats; Somatosensory Cortex; Substance P; Time Factors

1989